Clinical Trial Update: A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial assessing BAT4406F injection in adults with Minimal Change Disease and Focal Segmental Glomerulosclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Minimal Change Disease

Drugs mentioned

• BAT4406F (BAT4406F)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2, Phase 3 | Status: RECRUITING